Research programme: labdane diterpene therapeutics - MedexisAlternative Names: G200; Gerolab Project; Labdane diterpene therapeutics research programme - Medexis Biotech; MED-G200
Latest Information Update: 04 Feb 2011
At a glance
- Originator Medexis
- Class Diterpenes
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Aug 2004 Preclinical trials in Cancer in Greece (unspecified route)